双侧髂动脉分支装置治疗主髂动脉瘤安全可行且手术量不影响疗效:pELVIS国际多中心注册研究早中期结果
基于pELVIS国际多中心注册数据,纳入96例接受双侧髂动脉分支装置(IBD)植入的主髂动脉瘤患者,按中心手术量分为A组(65例)和B组(31例)。结果显示30天仅1例死亡,两组主要并发症无显著差异;2年免于IBD相关I型内漏和IBD一期通畅率分别为96%和92%,组间无显著差异,手术量不影响技术或临床疗效。
要点
- 双侧IBD植入在主髂动脉瘤解剖合适患者中安全可行,30天死亡率极低。
- 2年IBD相关I型内漏免除率96%,一期通畅率92%,IBD相关再干预免除率83%。
- 高手术量中心与低手术量中心在主要并发症及随访结局上无显著差异。
核心结论
- 在pELVIS注册研究中,双侧IBD同期植入治疗主髂动脉瘤安全可行,中期随访IBD相关不良事件率低。
- 手术量似乎不影响双侧IBD植入后的技术或临床结局,该技术仍是特定患者的有利治疗选择。
研究设计与样本
- 研究基于pELVIS国际多中心注册数据,仅分析接受同期双侧IBD植入的患者。
- 共纳入96例患者(来自整个pELVIS队列的910例手术),其中A组65例,B组31例。
- 中心分类:A组为完成>10例和/或>20%同期双侧IBD手术的中心,否则为B组。
主要发现
- 30天内仅1例死亡;9例患者发生至少1种主要并发症,A组与B组分别为10.8% vs 6.5%(p=0.714)。
- 整体队列2年免于IBD相关I型内漏为96%,IBD一期通畅率为92%。
- A组与B组2年免于IBD相关I型内漏分别为95% vs 100%(p=0.335),一期通畅率分别为93% vs 88%(p=0.470)。
- 2年免于任何IBD相关再干预为83%,两组分别为85% vs 83%(p=0.904)。
临床怎么用
- 对于解剖合适的主髂动脉瘤患者,可考虑同期双侧IBD植入作为治疗选择。
- 中心手术量不应作为限制双侧IBD开展的因素,但需注意技术复杂性。
局限性
- 研究为注册研究,样本量有限(96例),可能存在选择偏倚。
- 中心手术量分组标准基于>10例和/或>20%的比例,非随机分组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate early and follow-up outcomes following bilateral use of iliac branch devices (IBD) for aortoiliac endografting and assess the impact of center volume. We used data from the pELVIS international multicentric registry. METHODS: For the purpose of this study, only those patients receiving concomitant bilateral IBD implantation were analyzed. To assess the impact that procedural volume of bilateral IBD implantation could have on early and follow-up outcomes, participating institutions were classified as Site(s) A if they had performed >10 and/or >20% concomitant bilateral IBD procedure, otherwise they were classified as Site(s) B. Endpoints of the analysis included early (ie, 30-day) mortality and morbidity, as well as all-cause and aneurysm-related mortality during follow-up. Additional endpoints that were evaluated included IBD-related reinterventions, IBD occlusion or stenosis requiring reintervention (ie, loss of primary patency), and IBD-related type I endoleak. RESULTS: Overall, 96 patients received bilateral IBD implantation (out of 910 procedures collected in the whole pELVIS cohort), of whom 65 were treated at Site A (ie, Group A) and 31 were treated at Site(s) B (ie, Group B). In total, only 1 death occurred within 30 days from bilateral IBD implantation, and 9 patients experienced at least 1 major complication without any significant difference between subjects in Group A versus those in Group B (10.8% vs 6.5%, p=0.714). In the overall cohort, the 2-year freedom from IBD-related type I endoleaks and IBD primary patency were 96% and 92%, respectively; no significant differences were seen in those rates between Group A or Group B (95% vs 100%, p=0.335; 93% vs 88%, p=0.470). Freedom from any IBD-related reinterventions was 83% at 2 years, with similar rates between study groups (85% vs 83%, p=0.904). CONCLUSIONS: Within the pELVIS registry, concomitant bilateral IBD implantation is a safe and feasible technique for management of aortoiliac aneurysms in patients with suitable anatomy. Despite increased technical complexity, effectiveness of the repair is satisfactory with low rates of IBD-related adverse events at mid-term follow-up. Procedural volume does not seem to affect technical or clinical outcomes after bilateral use of IBD, which remains a favorable treatment option in selected patients.
引用
- D'Oria M, Pitoulias GA, Torsello GF, et al. Bilateral Use of Iliac Branch Devices for Aortoiliac Aneurysms Is Safe and Feasible, and Procedural Volume Does Not Seem to Affect Technical or Clinical Effectiveness: Early and Midterm Results From the pELVIS International Multicentric Registry. J Endovasc Ther. 2021. PMID: 34060354. doi:10.1177/15266028211016439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。